Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

utcome measures the low-dose group showed a demonstrable, but more modest treatment effect than the high-dose group. Regarding safety, low-dose pirfenidone was also safe and generally well tolerated with overall fewer side effects than the high-dose group.

Steve Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "While the primary endpoint was met in just one of two CAPACITY studies, there are significant consistencies across the two studies in the overall treatment effect of pirfenidone on lung function and exercise tolerance. In addition, the Study Week 48 results from both CAPACITY studies are consistent with those of the primary efficacy endpoint, change in Vital Capacity at Week 52, in the Shionogi Phase 3 study. Considering the favorable safety profile of pirfenidone and the lack of any approved treatment options for IPF patients, we believe the collective data suggest pirfenidone may play a meaningful role in the management of patients suffering from this devastating disease."

Dr. Porter continued, "We are greatly indebted to the many patients, health care providers and study personnel who dedicated themselves to the successful conduct of the CAPACITY program and enabled us to deliver high quality data."

About CAPACITY and RECAP

The CAPACITY program consisted of two multinational, randomized, double-blind, placebo-controlled Phase 3 trials, named CAPACITY 1 and CAPACITY 2, designed to evaluate the safety and efficacy of pirfenidone in IPF patients with mild to moderate impairment in lung function. The primary endpoint of both trials was change in percent predicted Forced Vital Capacity (FVC) after 72 weeks of treatment evaluated with a nonparametric rank ANCOVA analysis. Both trials enrolled patients in North America, Europe and Australia with roughly 75% of the total 779 patients enrolled in North America.

CAPACITY 1 enrolled a total of 344 patients. Pati
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Md., Dec. 4 MedImmune today announced that,it has ... chronic asthma to,determine the safety of subcutaneous dosing of ... (IL-5R). Preclinical data,suggest that inhibiting the IL-5R pathway may ... supporting continued study of this antibody. , ...
... Azur Pharma Limited ("Azur") today,announced that it has ... ("BioSante")(Nasdaq: BPAX ) to acquire U.S. ... formulation of estradiol which is,indicated for the treatment ... Elestrin was approved by the U.S. Food and ...
... Introduces New Trade Name Onrigin(TM) for Laromustine , , ... (OTC Bulletin Board: VION) today made several announcements related to events ... the Moscone Center in San Francisco from December 6-9, 2008. ... , , The Company announced ...
Cached Biology Technology:MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 3Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 4
(Date:4/23/2014)... study by a University of Exeter researcher has shed ... wild camels thriving in Australia,s remote outback have become ... , Sarah Crowley, of the Environment and Sustainability Institute ... history of the camel in Australia, from their historic ... their current status as unwelcome "invader." , The deserts ...
(Date:4/23/2014)... (April 23, 2014). "I think one can argue that if ... as doing everything else that we canthen we can solve ... one of the world,s foremost climate researchers, in the current ... by SAGE. Refusing to take significant action on climate change ... needed to address the problem, Wigley explains in an exclusive ...
(Date:4/22/2014)... April 22, 2014 Scientists from the Florida campus ... protein complex that plays a critical but previously unknown ... study, which showed a novel role for a protein ... the journal eLife , a publisher supported by ... and the Wellcome Trust. , "This is a critical ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Is nuclear power the only way to avoid geoengineering? 2Scientists identify critical new protein complex involved in learning and memory 2
... months of the First World War, a lethal virus ... swept the United States, Europe and Asia in three ... claimed up to 100 million victims, most of whom ... pneumonia. Many died within days of the first symptoms. ...
... by too many people, according to a new report published ... a Cell Press publication. Rather, the researchers found that the ... Indian Ocean depended mostly on the complexity of the reefs ... the shores., Specifically, they found, overfishing is at its worst ...
... to direct chemical modifications to specific sites on recombinant ... the pharmaceutical industry has been developed by Carolyn ... Energy,s Lawrence Berkeley National Laboratory and the University of ... for diabetes, can be made in bacterial systems like ...
Cached Biology News:Shades of 1918? New study compares avian flu with a notorious killer from the past 2Shades of 1918? New study compares avian flu with a notorious killer from the past 3Shades of 1918? New study compares avian flu with a notorious killer from the past 4Shades of 1918? New study compares avian flu with a notorious killer from the past 5Rise or fall of reef fish driven by both economy and ecology 2Tailor-made recombinant proteins in mammals 2Tailor-made recombinant proteins in mammals 3Tailor-made recombinant proteins in mammals 4
... Quansys Biosciences Q-Plex Array is a new ... human, mouse, and rat research. The Q-Plex ... ELISA-based test where 4 distinct capture antibodies ... a 96-well plate in a defined array. ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
...
Biology Products: